In patients receiving palliative care, individualized management of delirium precipitants and supportive strategies result in lower scores and shorter duration of target distressing delirium symptoms than when risperidone or haloperidol are added.

247 participants were included in intention-to-treat analysis (82 receiving risperidone, 81 receiving haloperidol, and 84 receiving placebo).

Improvement in mean group difference of delirium symptom score (severity range, 0-6) between baseline and day 3.

Five a priori secondary outcomes: delirium severity, midazolam use, extrapyramidal effects, sedation, and survival.

Read More